NCT03471260 2026-03-11Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesM.D. Anderson Cancer CenterPhase 1/2 Recruiting96 enrolled
NCT02677922 2026-02-19A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction ChemotherapyCelgenePhase 1/2 Active not recruiting130 enrolled 38 charts